LIFE — aTyr Pharma Income Statement
0.000.00%
Last trade - 00:00
- $106.67m
- $10.24m
- $0.35m
- 26
- 13
- 65
- 27
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.422 | 10.5 | 0 | 10.4 | 0.353 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 23.4 | 26.4 | 34 | 56.8 | 55.3 |
Operating Profit | -23 | -15.9 | -34 | -46.4 | -54.9 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -23.8 | -16.2 | -33.8 | -45.3 | -50.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -23.8 | -16.2 | -33.8 | -45.3 | -50.4 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -23.6 | -16.2 | -33.8 | -45.3 | -50.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -23.6 | -16.2 | -33.8 | -45.3 | -50.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -7.03 | -1.77 | -1.77 | -1.6 | -0.94 |